Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting.
about
Galantamine slows down plaque formation and behavioral decline in the 5XFAD mouse model of Alzheimer's disease.Long-term effect of galantamine on cognitive function in patients with Alzheimer's disease versus a simulated disease trajectory: an observational study in the clinical setting.Effectiveness and Safety of MLC601 in the Treatment of Mild to Moderate Alzheimer's Disease: A Multicenter, Randomized Controlled Trial.Progression of mild Alzheimer's disease: knowledge and prediction models required for future treatment strategies.Prediction models for assessing long-term outcome in Alzheimer's disease: a review.Nature as a source of metabolites with cholinesterase-inhibitory activity: an approach to Alzheimer's disease treatment.Nasal Application of the Galantamine Pro-drug Memogain Slows Down Plaque Deposition and Ameliorates Behavior in 5X Familial Alzheimer's Disease Mice.Long-Term Efficacy of Galantamine in Alzheimer's Disease: The Okayama Galantamine Study (OGS).Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years.Galantamine treatment in outpatients with mild Alzheimer's disease.First in human study with a prodrug of galantamine: Improved benefit-risk ratio?Efficacy and safety of galantamine treatment for patients with Alzheimer's disease: a meta-analysis of randomized controlled trials.
P2860
Q28540060-DADD1D70-3166-4447-A18D-660857B8A887Q33596862-9001C9C5-333A-48BE-B6A1-BE7B1B4E2874Q35276747-806AEA15-50E0-42ED-A6C8-54011D3D7AFDQ37690649-17D37D14-8DB9-4D9A-8C90-66974C883A46Q38108098-07BA74AC-3546-47E2-985F-36D9AEB7B1E4Q38162960-327D1E53-7D73-43B5-B8AC-28EF9739F088Q39193474-F7209D06-04BB-4060-8A18-431B32757D36Q41325631-2F56F570-9330-4A00-BD1D-24DC83BF0D0CQ41588156-A0B9590C-B34C-4377-99CC-2322AE0DA899Q42639500-61063C74-577F-461C-A085-95563B3C2416Q42689680-30D2B02F-1B26-4FEE-A7B8-7D9B3869BAB6Q50604148-BC507BB4-3548-47A8-8D47-598B00FBDD30
P2860
Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Galantamine treatment in Alzhe ...... in a routine clinical setting.
@ast
Galantamine treatment in Alzhe ...... in a routine clinical setting.
@en
type
label
Galantamine treatment in Alzhe ...... in a routine clinical setting.
@ast
Galantamine treatment in Alzhe ...... in a routine clinical setting.
@en
prefLabel
Galantamine treatment in Alzhe ...... in a routine clinical setting.
@ast
Galantamine treatment in Alzhe ...... in a routine clinical setting.
@en
P2860
P356
P1476
Galantamine treatment in Alzhe ...... in a routine clinical setting.
@en
P2093
Asa K Wallin
Carina Wattmo
P2860
P304
P356
10.2147/NDT.S24196
P407
P577
2011-09-30T00:00:00Z